Insider Selling: Mereo BioPharma Group plc (NASDAQ:MREO) General Counsel Sells 9,980 Shares of Stock

Mereo BioPharma Group plc (NASDAQ:MREO) General Counsel Charles Sermon sold 9,980 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $4.47, for a total transaction of $44,610.60. Following the completion of the sale, the general counsel now owns 240,007 shares in the company, valued at $1,072,831.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Charles Sermon also recently made the following trade(s):

• On Tuesday, June 25th, Charles Sermon sold 14,202 shares of Mereo BioPharma Group stock. The shares were sold at an average price of $3.69, for a total transaction of $52,405.38.

Mereo BioPharma Group Stock Performance

NASDAQ MREO opened at $3.95 on Wednesday. Mereo BioPharma Group plc has a 52 week low of $3.64 and a 52 week high of $5.02. The stock’s 50 day moving average price is $4.21 and its two-hundred day moving average price is $3.61.

Analyst Ratings Changes

A number of research analysts have issued reports on MREO shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a research note on Monday. Leerink Partners boosted their price objective on Mereo BioPharma Group from $6.00 to $8.00 and gave the company an “outperform” rating in a research report on Thursday, June 20th. Baird R W raised Mereo BioPharma Group to a “strong-buy” rating in a research note on Thursday, June 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $7.00 price target on shares of Mereo BioPharma Group in a research note on Tuesday, August 13th. Finally, Robert W. Baird began coverage on shares of Mereo BioPharma Group in a research report on Thursday, June 13th. They set an “outperform” rating and a $8.00 price objective for the company. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $7.50.

Institutional Trading of Mereo BioPharma Group

A number of institutional investors have recently made changes to their positions in the business. Rhumbline Advisers increased its stake in Mereo BioPharma Group by 70.9% in the 2nd quarter. Rhumbline Advisers now owns 6,958 shares of the company’s stock valued at $25,000 after buying an additional 2,887 shares during the last quarter. Advisors Preferred LLC bought a new position in shares of Mereo BioPharma Group in the 1st quarter valued at about $28,000. SG Americas Securities LLC acquired a new stake in shares of Mereo BioPharma Group in the first quarter valued at about $54,000. BNP Paribas Financial Markets raised its holdings in Mereo BioPharma Group by 581,066.7% during the first quarter. BNP Paribas Financial Markets now owns 17,435 shares of the company’s stock worth $58,000 after acquiring an additional 17,432 shares in the last quarter. Finally, Index Fund Advisors Inc. acquired a new position in Mereo BioPharma Group during the first quarter valued at approximately $99,000. Institutional investors own 62.83% of the company’s stock.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.